Stock Alert: Hepion Pharma Jumps 35%

(RTTNews) - Shares of Hepion Pharmaceuticals, Inc. (HEPA) are rising over 35% on Tuesday morning. The biopharmaceutical company announced that its anti-fibrotic drug candidate was efficacious in two pre-clinical research related to COVID-19.

HEPA is currently trading at $3.93, up $1.05 or 36.4583%, on the Nasdaq.

Hepion, a pharma company focusing on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis, said its clinical phase, anti-fibrotic drug candidate, CRV431, was efficacious in two distinct preclinical research models related to COVID-19 disease.

Firstly, CRV431 demonstrated strong anti-inflammatory actions in a non-viral, acute lung injury model and on some measures outperformed dexamethasone, a recently recommended treatment for COVID-19.

Secondly, cell culture experiments demonstrated CRV431 antiviral activity towards SARS-CoV-2, the virus responsible for COVID-19 disease.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.